Group One Trading’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-83
Closed -$860 8253
2025
Q3
$860 Buy
+83
New +$772 ﹤0.01% 8080
2025
Q1
Sell
-6,173
Closed -$139K 7691
2024
Q4
$139K Buy
6,173
+6,063
+5,512% +$191K ﹤0.01% 4240
2024
Q3
$4.13K Buy
110
+47
+75% +$1.8K ﹤0.01% 5950
2024
Q2
$2.38K Sell
63
-224
-78% -$8.15K ﹤0.01% 6177
2024
Q1
$9.63K Buy
287
+4
+1% +$145 ﹤0.01% 5887
2023
Q4
$11.3K Buy
283
+280
+9,333% +$9.87K ﹤0.01% 6123
2023
Q3
$106 Buy
+3
New +$113 ﹤0.01% 7474
2023
Q1
Sell
-223
Closed -$16.9K 7303
2022
Q4
$16.9K Sell
223
-1,690
-88% -$158K ﹤0.01% 5703
2022
Q3
$184K Buy
1,913
+313
+20% +$43.8K ﹤0.01% 4222
2022
Q2
$269K Sell
1,600
-363
-18% -$55.2K ﹤0.01% 4011
2022
Q1
$364K Sell
1,963
-1,464
-43% -$303K ﹤0.01% 4172
2021
Q4
$918K Sell
3,427
-50
-1% -$13.1K ﹤0.01% 3447
2021
Q3
$1.01M Sell
3,477
-10
-0.3% -$2.92K ﹤0.01% 3397
2021
Q2
$863K Buy
3,487
+87
+3% +$22.4K ﹤0.01% 3584
2021
Q1
$973K Buy
3,400
+1,707
+101% +$681K ﹤0.01% 3268
2020
Q4
$472K Sell
1,693
-324
-16% -$120K ﹤0.01% 3315
2020
Q3
$822K Sell
2,017
-70
-3% -$36K ﹤0.01% 2381
2020
Q2
$1.21M Buy
2,087
+1,880
+908% +$858K 0.01% 1861
2020
Q1
$47K Buy
+207
New +$35.9K ﹤0.01% 3754

Other funds holding CODX

Group One Trading's CODX Position: Q4 2025 in Review

Group One Trading sold out of Co-Diagnostics (CODX) in Q4 2025, closing a stake of 1,810 shares — an estimated $19.7K sold.

Group One Trading first reported a position in CODX in Q1 2021 and held it in 16 quarters. The position peaked at $657K in Q1 2021. 30 funds tracked by Wall St. Rank hold CODX as of Q4 2025.

  • Group One Trading reported no remaining Co-Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 1,810 Co-Diagnostics shares in Q4 2025, an estimated $19.7K.
  • Group One Trading first reported a position in Co-Diagnostics in Q1 2021 and held it in 16 quarters.
  • Group One Trading's Co-Diagnostics position peaked at $657K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.